CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing
This article was originally published in PharmAsia News
Executive Summary
TOKYO - CSL closed its 2010 fiscal year with a mixed bag of results. From gains in its plasma portfolio to disappointments in Gardasil and influenza vaccines, the Melbourne, Australia-based company's 2011 outlook is a combination of caveats and prospects
You may also be interested in...
Abbott, Baxter, Bristol-Myers Squibb: Emerging Markets Earnings Roundup (Part 1 of 3)
A push in emerging markets continued in the second quarter with Big Pharma reporting flat U.S. sales and a challenging payer environment in Europe, with many reallocating resources in Asia and forming more Asia partnerships. As a recurring feature, PharmAsia News combs through quarterly earnings reports to bring together the earning season's Asia highlights.
U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine
PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).